IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) — Cyborg Score 3/10
Weak
Biopharmaceutical / Clinical Stage Pharmaceutical Development
Strategic Profile
The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's, with pre-clinical stage product candidates including TGR-63, IGC-M3, and LMP to treat Alzheimer's disease. As a micro-cap biotech player, IGC Pharma is pursuing high-risk, high-reward clinical development in a large therapeutic market with significant unmet medical needs in Alzheimer's treatment.
Cyborg Score Rationale
The company operates as a pre-revenue clinical stage pharmaceutical with minimal market capitalization (~$26M) and historically volatile stock performance. While it has focused pipeline assets in a large market, execution risk is substantial and financial resources are severely constrained for biotech development.
Top Insights
Company rebranded to IGC Pharma in March 2023, marking strategic pivot from diversified commodities to pure-play pharmaceutical focus
Lead candidate IGC-AD1 has reached Phase II trials, representing material clinical progress for a micro-cap biotech
Stock trading near penny stock levels (~$0.25-0.50 range) with <$30M market cap, indicating significant financial constraints and distress
Company serves niche but large Alzheimer's disease market where competition is intense but unmet medical needs remain substantial
Named Competitors
Lecanemab (Leqembi) — Approved amyloid-targeting monoclonal antibody for early Alzheimer's
Donanemab — Investigational amyloid-targeting antibody in late-stage development
Various antipsychotic/behavioral therapies — Standard treatments for agitation in dementia
Recent Developments
(February 2026) IGC Pharma held Q4 2025 earnings call highlighting strategic focus on Alzheimer's disease treatments
(2026) Phase 2 CALMA trial for IGC-AD1 reached 70% enrollment with expansion to new clinical trial sites
(March 2023) Company completed name change from India Globalization Capital to IGC Pharma, Inc.
Open the full interactive IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.